Physician profile
Pascale Daou
NPI 1104597491
$8,426.35
in general payments reported to CMS, 2019-2025
27 companies · $3,130 in 2025
The $3,130 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,946 · 2024: $3,350 · 2025: $3,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,231 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,231.25 |
| Education | $195.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,867.90 | 2023-2025 | |
| Janssen Biotech, INC. | $1,724.80 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,189.23 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $755.13 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Lilly USA, LLC | $526.02 | 2023-2025 | Omvoh, Zepbound, Mounjaro |
| Qol Medical, LLC | $522.12 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $326.01 | 2023-2025 | Ibsrela |
| Celgene Corporation | $256.11 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $165.18 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $163.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $161.52 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $107.37 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $72.44 | 2023-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $69.53 | 2023-2024 | Linzess |
| Mauna Kea Technologies, INC. | $63.78 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $58.71 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $53.71 | 2025 | |
| Evoke Pharma, INC. | $53.11 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $52.70 | 2023-2024 | Ocaliva |
| Celltrion USA INC. | $48.41 | 2024-2025 | Vegzelma, Zymfentra |
| Mirum Pharmaceuticals, INC. | $44.91 | 2024 | Livmarli |
| Ferring Pharmaceuticals INC. | $41.68 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $28.52 | 2024 | Dificid |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Daiichi Sankyo INC. | $24.99 | 2025 | Injectafer |
| Novo Nordisk INC | $13.52 | 2024 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascale Daou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.